<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935675</url>
  </required_header>
  <id_info>
    <org_study_id>TADDOR</org_study_id>
    <secondary_id>CSET 1388</secondary_id>
    <nct_id>NCT00935675</nct_id>
  </id_info>
  <brief_title>Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months in&#xD;
      patients with head and neck squamous cell carcinomas (oral cavity, larynx, oropharynx and&#xD;
      hypopharynx) and with an HADS total score &gt; 11&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Carcinomas</condition>
  <arm_group>
    <arm_group_label>Antidepressant treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Escitalopram 10 mg once a day</description>
    <arm_group_label>Antidepressant treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Head and neck squamous cell carcinomas, stage I to IVb&#xD;
&#xD;
          2. First-line curative cancer therapy : surgery and/or brachytherapy and/or chemotherapy&#xD;
&#xD;
          3. HADS- T &gt;11&#xD;
&#xD;
          4. Aged 18 to 75 yo, written consent required&#xD;
&#xD;
          5. OMS&gt;2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Palliative care&#xD;
&#xD;
          2. Previous head and neck cancer&#xD;
&#xD;
          3. Bipolar disorder or schizophrenia&#xD;
&#xD;
          4. Severe major depressive disorder (DSM-IV TR)&#xD;
&#xD;
          5. Expressed suicidal ideation&#xD;
&#xD;
          6. Severe untreated organic disorder, especially acute infectious disorder&#xD;
&#xD;
          7. ASAT/ALAT &gt; 3N&#xD;
&#xD;
          8. Clearance of creatinin &lt; 30 ml/mn&#xD;
&#xD;
          9. Hyponatremia&#xD;
&#xD;
         10. Antecedent of delirium tremens or acute alcohol withdrawal disorder&#xD;
&#xD;
         11. Antecedent of upper gastro-intestinal bleeding&#xD;
&#xD;
         12. Antecedent of toxicity or inefficacy of a previous treatment with escitalopram&#xD;
&#xD;
         13. Unauthorized treatments :- Antidepressant or antiepileptic (clonazepam authorized)-&#xD;
             Hypnotic except zolpidem - Anxiolytic except clonazepam, clorazepate or diazepam-&#xD;
             bupropion or varenicline&#xD;
&#xD;
         14. Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah DAUCHY, MD</last_name>
      <phone>33 1 42 11 40 53</phone>
      <email>sarah.dauchy@igr.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.igr.fr/</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>SARAH DAUCHY MD</name_title>
  </responsible_party>
  <keyword>Patients with head and neck squamous cell carcinomas</keyword>
  <keyword>head and neck squamous cell carcinomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

